Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Breast Neoplasms 1223Neoplasms 1041Carcinoma, Non-Small-Cell Lung 755Prostatic Neoplasms 693Colorectal Neoplasms 593Lung Neoplasms 574Pancreatic Neoplasms 402Leukemia, Myeloid, Acute 399Neoplasm Metastasis 387Multiple Myeloma 374Ovarian Neoplasms 372Stomach Neoplasms 317Carcinoma, Hepatocellular 303Melanoma 282Recurrence 281Brain Neoplasms 281Squamous Cell Carcinoma of Head and Neck 268Head and Neck Neoplasms 237Endometrial Neoplasms 235Glioblastoma 234Triple Negative Breast Neoplasms 230Precursor Cell Lymphoblastic Leukemia-Lymphoma 226Uterine Cervical Neoplasms 225Lymphoma 224Hematologic Neoplasms 200Sarcoma 199Urinary Bladder Neoplasms 197Esophageal Neoplasms 191Carcinoma, Renal Cell 190Lymphoma, Non-Hodgkin 176

Interventions

durvalumab 1Surgical Procedures, Operative 1Specimen Handling 1Platinum 1Magnetic Resonance Spectroscopy 1Immunoglobulin G 1Gemcitabine 1Disulfides 1Cisplatin 1Capecitabine 1Biopsy 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Resectable Intrahepatic Cholangiocarcinoma × 1 year × Clear all
NCT06050252 2026-05-22

Testing the Combination of the Anticancer Drug Durvalumab With Chemotherapy (Gemcitabine and Cisplatin) at Improving Outcomes for High-Risk Resectable Liver Cancer Before Surgery

National Cancer Institute (NCI)

Phase 2 Recruiting
27 enrolled
Gastrointestinal

Resectable Intrahepatic Cholangiocarcinoma

NCT05265208 2025-08-06

SIROCHO

Center Eugene Marquis

Phase 2 Recruiting
62 enrolled
Gastrointestinal

Resectable Intrahepatic Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡